(RTTNews) - Certara, Inc. (CERT),on Tuesday announced the release of Simcyp Simulator Version 24, enhancing physiologically-based pharmacokinetic or PBPK modeling to support drug development and regulatory decision-making.
The updated Simcyp Simulator introduces advanced capabilities for biopharmaceutics, drug-drug interaction or DDI, and biologics modeling, helping pharmaceutical companies and regulators optimize drug development strategies.
Key enhancements include:
-- Including improved Virtual Bioequivalence or VBE modeling for predicting food effects on drug absorption. -- Incorporating new and refined enzyme and transporter compound files for more accurate interaction modeling in the gut, liver, and kidney.
-- Enhancing simulations of membrane-bound targets, drug-target interactions, and target-mediated drug disposition.
-- Offering improved simulation efficiency and flexibility.
-- Expanded capabilities for pediatric, pregnancy, and lactation populations.
-- Performance and usability upgrades, including a modernized UI, cloud computing integration, and an AI-powered 'Ask Simcyp' support chat.
-- Improved route of administration modeling, covering long-acting injectables, inhalation, and ocular drug delivery.
Certara highlighted that four out of five drugs utilizing PBPK for FDA approval in recent years have used Simcyp Simulator, which has contributed to over 120 FDA-approved novel drugs and supported clinical trial waivers in key areas such as DDI and pediatric trials.
With the latest updates, Simcyp Simulator V24 aims to strengthen its role as an essential tool in advancing drug development, regulatory approvals, and clinical decision-making.
Currently, CERT is trading at $9.78 down by 1.19 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
